Neurexis Therapeutics
PrivateLast Round
Grant
Sep 18, 2024
Total Funding Raised
$4.65M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Neurexis Therapeutics is a biotechnology company that develops neuroprotective peptide therapeutics for the prevention of brain damage following ischemic events such as stroke and cardiac arrest.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neurexis Therapeutics Comparables
Compare Neurexis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Astrocyte Pharmaceuticals Inc. | 83% | |
| Infensa Bioscience | 79% | |
| NoNO Inc. | 78% | |
Neurexis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Sep 18, 2024 | ||||
| Grant | Apr 18, 2023 | ||||
| Series A | Mar 7, 2022 | ||||
| Grant | Oct 13, 2021 | ||||
| Grant | Jun 18, 2020 | ||||
Seed | Apr 8, 2020 |
Key People
Founding team and executive leadership
Neurexis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NIH RADx | Grant |
| Colorado Office of Economic Development and International Trade (OEDIT) | Grant |
| National Institute of Neurological Disorders and Stroke | Grant |
| VIC Technology Venture Development | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 29, 2026
Monthly visitors increased 132% MoM.
- May 18, 2026
Monthly visitors increased 147% MoM.
Neurexis Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Neurexis Therapeutics's valuation, stock price, and market status.